FDA Approves Lumvoa for Thyroid Eye Disease, Viridian to Launch Immediately
VRDN sits 43% above its 52-week low of $13.18 on elevated volume (1.9× avg).
Summary
The FDA has approved Lumvoa, Viridian's drug for Thyroid Eye Disease (TED), with an immediate launch planned. This approval, which includes data for both active and chronic TED, comes ahead of the previously announced June 30th PDUFA date for veligrotug (Lumvoa). This is a transformative event for Viridian, validating its lead asset and opening a significant commercial revenue stream. The company recently raised $350 million in early May, likely to fund this commercialization effort. Investors will be watching the June 29th conference call for details on the launch and financial projections.
At the time of this announcement, VRDN was trading at $18.91 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2B. The 52-week trading range was $13.18 to $34.29. This news item was assessed with positive market sentiment and an importance score of 10 out of 10. Source: Dow Jones Newswires.